Skip to content
PUBLISHED: | UPDATED:

Biodesix Inc. (Nasdaq: BDSX), a diagnostics company that specializes in lung disease, reported a 17% year-over-year increase in core revenue related to its lung diagnostics for the first quarter of 2022, to $4.6 million from $3.9 million.

Overall revenue for the first quarter declined 77% year-over-year, mostly due to a 96% decrease in revenue from COVID-19 diagnostics “in line with expectations as the pandemic recedes and COVID testing trends continue to move to at-home testing,” according to a news release.

Biodesix posted a net loss of $15.6 million for the quarter, up from $6.9 million in the first quarter of 2021. It has $16.4 million in cash and equivalents on hand.

The company expects to generate between $37.5 million and $39.5 million in revenue for the 2022 fiscal year.

This article was first published by BizWest, an independent news organization, and is published under a license agreement. © 2022 BizWest Media LLC.

Join the Conversation

We invite you to use our commenting platform to engage in insightful conversations about issues in our community. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable to us, and to disclose any information necessary to satisfy the law, regulation, or government request. We might permanently block any user who abuses these conditions.